{"result": {"id": "8b8aeba6-4955-41cb-aee3-f44b8347831d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>Lancet<|>ORGANIZATION<|>Lancet is a medical journal that published the ACCOMPLISH trial results<|>5)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a medical journal that published the STEP 8 trial results<|>5)\n##\n(\"entity\"<|>N Engl J Med<|>ORGANIZATION<|>New England Journal of Medicine published studies on tirzepatide and bariatric surgery outcomes<|>5)\n##\n(\"entity\"<|>PLoS Med<|>ORGANIZATION<|>PLoS Medicine published meta-analysis on bariatric surgery outcomes<|>5)\n##\n(\"entity\"<|>BMJ Open<|>ORGANIZATION<|>BMJ Open published research on metabolic syndrome and cardiovascular disease in China<|>5)\n##\n(\"entity\"<|>Eur J Clin Invest<|>ORGANIZATION<|>European Journal of Clinical Investigation published research on metabolic syndrome and CKD progression<|>5)\n##\n(\"entity\"<|>Ann Med<|>ORGANIZATION<|>Annals of Medicine published research on metabolic syndrome prevalence in China<|>5)\n##\n(\"entity\"<|>Cardiovasc Diabetol<|>ORGANIZATION<|>Cardiovascular Diabetology published the GOOD survey and EMPA-REG OUTCOME analyses<|>5)\n##\n(\"entity\"<|>Pharmacol Res<|>ORGANIZATION<|>Pharmacological Research published studies on blood pressure control in diabetes<|>5)\n##\n(\"entity\"<|>Can J Cardiol<|>ORGANIZATION<|>Canadian Journal of Cardiology published research on hypertension from antiangiogenic therapy<|>5)\n##\n(\"entity\"<|>Am J Hypertens<|>ORGANIZATION<|>American Journal of Hypertension published meta-analysis on bevacizumab-induced hypertension<|>5)\n##\n(\"entity\"<|>人民军医出版社<|>ORGANIZATION<|>People's Military Medical Press published 祝之明's book on metabolic syndrome<|>5)\n##\n(\"entity\"<|>中华流行病学杂志<|>ORGANIZATION<|>Chinese Journal of Epidemiology published research on metabolic syndrome components<|>5)\n##\n(\"entity\"<|>J Sports Sci<|>ORGANIZATION<|>Journal of Sports Sciences published research on physical activity and metabolic syndrome<|>5)\n##\n(\"entity\"<|>中华心血管病杂志<|>ORGANIZATION<|>Chinese Journal of Cardiology published 祝之明's work on metabolic cardiovascular diseases<|>5)\n##\n(\"relationship\"<|>ACCOMPLISH<|>Lancet<|>ACCOMPLISH trial results were published in Lancet<|>8)\n##\n(\"relationship\"<|>STEP 8<|>JAMA<|>STEP 8 trial results were published in JAMA<|>8)\n##\n(\"relationship\"<|>Tirzepatide<|>N Engl J Med<|>Tirzepatide obesity treatment study was published in NEJM<|>8)\n##\n(\"relationship\"<|>Bariatric Surgery<|>N Engl J Med<|>Bariatric surgery outcomes were published in NEJM<|>8)\n##\n(\"relationship\"<|>Bariatric Surgery<|>PLoS Med<|>Bariatric surgery meta-analysis was published in PLoS Medicine<|>8)\n##\n(\"relationship\"<|>Metabolic Syndrome<|>BMJ Open<|>Metabolic syndrome research was published in BMJ Open<|>8)\n##\n(\"relationship\"<|>Metabolic Syndrome<|>Eur J Clin Invest<|>Metabolic syndrome and CKD research was published in EJCI<|>8)\n##\n(\"relationship\"<|>Metabolic Syndrome<|>Ann Med<|>Metabolic syndrome prevalence study was published in Annals of Medicine<|>8)\n##\n(\"relationship\"<|>GOOD SURVEY<|>Cardiovasc Diabetol<|>GOOD survey results were published in Cardiovascular Diabetology<|>8)\n##\n(\"relationship\"<|>EMPA-REG OUTCOME<|>Cardiovasc Diabetol<|>EMPA-REG OUTCOME analysis was published in Cardiovascular Diabetology<|>8)\n##\n(\"relationship\"<|>Blood Pressure Control<|>Pharmacol Res<|>Blood pressure control research was published in Pharmacological Research<|>8)\n##\n(\"relationship\"<|>Hypertension<|>Can J Cardiol<|>Hypertension from antiangiogenic therapy was published in Canadian Journal of Cardiology<|>8)\n##\n(\"relationship\"<|>Hypertension<|>Am J Hypertens<|>Bevacizumab-induced hypertension meta-analysis was published in AJH<|>8)\n##\n(\"relationship\"<|>祝之明<|>人民军医出版社<|>祝之明's book on metabolic syndrome was published by People's Military Medical Press<|>8)\n##\n(\"relationship\"<|>Metabolic Syndrome<|>中华流行病学杂志<|>Metabolic syndrome component research was published in Chinese Journal of Epidemiology<|>8)\n##\n(\"relationship\"<|>Metabolic Syndrome<|>J Sports Sci<|>Physical activity and metabolic syndrome research was published in Journal of Sports Sciences<|>8)\n##\n(\"relationship\"<|>祝之明<|>中华心血管病杂志<|>祝之明's work on metabolic cardiovascular diseases was published in Chinese Journal of Cardiology<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559192, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1207, "prompt_tokens": 6840, "total_tokens": 8047, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 6784}, "prompt_cache_hit_tokens": 6784, "prompt_cache_miss_tokens": 56}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , 17\n(10) :1001-1011.\n[616]  WeberMA, JamersonK, BakrisGL, etal. Effectsofbodysize andhypertensiontreatmentsoncardiovasculareventrates: suba- nalysisof the ACCOMPLISH randomised controlled trial[J].   Lancet,2013,381(9866) :537-545.\n[617]  RubinoDM, Greenway FL, Khalid U, et al.  Effectofweekly subcutaneoussemaglutidevs daily liraglutide on body weightin adultswith overweightorobesitywithoutdiabetes: theSTEP 8 randomized clinicaltrial[J]. JAMA,2022,327(2) :138-150.\n[618] JastreboffAM, AronneLJ, AhmadNN, etal. Tirzepatideonce weeklyforthetreatmentofobesity[J]. NEnglJ Med,2022,387\n(3) :205-216.\n[619]  WigginsT, GuidozziN, WelbournR, etal. Associationofbari- atricsurgerywithall-causemortalityandincidenceofobesity-re- lateddiseaseatapopulationlevel: asystematicreview andmeta- analysis[J]. PLoSMed,2020,17(7) :e1003206.\n[620]  Sj?str?m L, LindroosAK, Peltonen M, etal. Lifestyle, diabe- tes, and cardiovascular risk factors10 years afterbariatric sur- gery[J]. N EnglJ Med,2004,351(26) :2683-2693.\n[621]  LiW , SongF, WangX, etal. Relationship between metabolic syndromeand itscomponentsand cardiovasculardiseasein mid- dle-agedandelderlyChinesepopulation: anationalcross-section- alsurvey[J]. BMJ Open,2019,9(8) :e027545.\n[622]  Wu M, Shu Y, Wang L,  et al.  Metabolic syndrome severity scoreand theprogressionofCKD[J]. EurJClin Invest,2022,52\n(1) :e13646.\n[623]  LiW , Song F, Wang X,  et al.  Prevalence of metabolic syn-\n\n\ndromeamong middle-aged and elderly adults in China: current statusand temporaltrends[J]. Ann Med,2018,50(4) :345-353.\n[624]  祝之明.  代谢综合征-病因探索与临床实践[M]. 北京 :人民军医 出版社 ,2005:24-25.\n[625]  刘静 ,赵冬 ,王薇 ,等.  中国 11省市代谢综合征不同组分及其组  合形式与心血管病发病的关系[J]. 中华流行病学杂志 ,2008,29\n(7) :652-655.\n[626]  XiaoJ, WuC, XuG, etal. Associationofphysicalactivitywith risk of metabolic syndrome:  findings from  a cross-sectional study conducted in ruralarea, Nantong, China[J]. J SportsSci,  2016,34(19) :1839-1848.\n[627]  ZidekW , Naditch-Br?léL, PerliniS, etal. Bloodpressurecon- trolandcomponentsofthemetabolicsyndrome: theGOOD sur- vey[J]. CardiovascDiabetol,2009,8:51.\n[628]  FerreiraJP, VermaS, FitchettD, etal. Metabolicsyndromein patientswith type2 diabetes and atherosclerotic cardiovascular disease: aposthocanalysesoftheEMPA-REG OUTCOME tri- al[J]. CardiovascDiabetol,2020,19(1) :200.\n[629]  BerraC, ManfriniR, RegazzoliD, etal. Bloodpressurecontrol in type2 diabetes mellitus with arterialhypertension.  The im- portant ancillary role of SGLT2-inhibitors and GLP1-receptor agonists[J]. PharmacolRes,2020,160:105052.\n[630]  祝之明.  代谢性心血管病 :理念、挑战与实践[J]. 中华心血管病 杂志 ,2021,49(7) :650-655.\n[631]  SmallHY, MontezanoAC, RiosFJ, etal.  Hypertensiondueto antiangiogenic cancer therapy with vascular endothelialgrowth factorinhibitors: understanding and managing a new syndrome [J]. CanJ Cardiol,2014,30(5) :534-543.\n[632]  Ranpura V, PulipatiB, Chu D, et al.  Increased risk of high- grade hypertensionwithbevacizumab incancerpatients: ameta- analysis[J]. Am JHypertens,2010,23(5) :460-468.\n[633]  Maitland ML, BakrisGL, Black HR, etal. Initialassessment,  surveillance, and managementofblood pressure in patients\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ACCOMPLISH<|>EVENT<|>ACCOMPLISH is a randomised controlled trial investigating the effects of body size and hypertension treatments on cardiovascular event rates<|>5)\n##\n(\"entity\"<|>STEP 8<|>EVENT<|>STEP 8 is a randomized clinical trial comparing the effects of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes<|>5)\n##\n(\"entity\"<|>EMPA-REG OUTCOME<|>EVENT<|>EMPA-REG OUTCOME is a post-hoc analysis trial investigating metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease<|>5)\n##\n(\"entity\"<|>GOOD SURVEY<|>EVENT<|>GOOD SURVEY is a study examining blood pressure control and components of the metabolic syndrome<|>5)\n##\n(\"entity\"<|>WeberMA<|>PERSON<|>WeberMA is a researcher involved in the ACCOMPLISH trial<|>3)\n##\n(\"entity\"<|>JamersonK<|>PERSON<|>JamersonK is a researcher involved in the ACCOMPLISH trial<|>3)\n##\n(\"entity\"<|>BakrisGL<|>PERSON<|>BakrisGL is a researcher involved in the ACCOMPLISH trial and other hypertension-related studies<|>4)\n##\n(\"entity\"<|>RubinoDM<|>PERSON<|>RubinoDM is a researcher involved in the STEP 8 trial<|>3)\n##\n(\"entity\"<|>GreenwayFL<|>PERSON<|>GreenwayFL is a researcher involved in the STEP 8 trial<|>3)\n##\n(\"entity\"<|>KhalidU<|>PERSON<|>KhalidU is a researcher involved in the STEP 8 trial<|>3)\n##\n(\"entity\"<|>JastreboffAM<|>PERSON<|>JastreboffAM is a researcher involved in the study of tirzepatide for obesity treatment<|>3)\n##\n(\"entity\"<|>AronneLJ<|>PERSON<|>AronneLJ is a researcher involved in the study of tirzepatide for obesity treatment<|>3)\n##\n(\"entity\"<|>AhmadNN<|>PERSON<|>AhmadNN is a researcher involved in the study of tirzepatide for obesity treatment<|>3)\n##\n(\"entity\"<|>WigginsT<|>PERSON<|>WigginsT is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>3)\n##\n(\"entity\"<|>GuidozziN<|>PERSON<|>GuidozziN is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>3)\n##\n(\"entity\"<|>WelbournR<|>PERSON<|>WelbournR is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>3)\n##\n(\"entity\"<|>Sj?str?mL<|>PERSON<|>Sj?str?mL is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>3)\n##\n(\"entity\"<|>LindroosAK<|>PERSON<|>LindroosAK is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>3)\n##\n(\"entity\"<|>PeltonenM<|>PERSON<|>PeltonenM is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>3)\n##\n(\"entity\"<|>LiW<|>PERSON<|>LiW is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>4)\n##\n(\"entity\"<|>SongF<|>PERSON<|>SongF is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>4)\n##\n(\"entity\"<|>WangX<|>PERSON<|>WangX is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>4)\n##\n(\"entity\"<|>WuM<|>PERSON<|>WuM is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>3)\n##\n(\"entity\"<|>ShuY<|>PERSON<|>ShuY is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>3)\n##\n(\"entity\"<|>WangL<|>PERSON<|>WangL is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>3)\n##\n(\"entity\"<|>XiaoJ<|>PERSON<|>XiaoJ is a researcher involved in the study of physical activity and metabolic syndrome risk<|>3)\n##\n(\"entity\"<|>WuC<|>PERSON<|>WuC is a researcher involved in the study of physical activity and metabolic syndrome risk<|>3)\n##\n(\"entity\"<|>XuG<|>PERSON<|>XuG is a researcher involved in the study of physical activity and metabolic syndrome risk<|>3)\n##\n(\"entity\"<|>ZidekW<|>PERSON<|>ZidekW is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>3)\n##\n(\"entity\"<|>Naditch-Br?léL<|>PERSON<|>Naditch-Br?léL is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>3)\n##\n(\"entity\"<|>PerliniS<|>PERSON<|>PerliniS is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>3)\n##\n(\"entity\"<|>FerreiraJP<|>PERSON<|>FerreiraJP is a researcher involved in the EMPA-REG OUTCOME trial<|>3)\n##\n(\"entity\"<|>VermaS<|>PERSON<|>VermaS is a researcher involved in the EMPA-REG OUTCOME trial<|>3)\n##\n(\"entity\"<|>FitchettD<|>PERSON<|>FitchettD is a researcher involved in the EMPA-REG OUTCOME trial<|>3)\n##\n(\"entity\"<|>BerraC<|>PERSON<|>BerraC is a researcher involved in studies on blood pressure control in type 2 diabetes<|>3)\n##\n(\"entity\"<|>ManfriniR<|>PERSON<|>ManfriniR is a researcher involved in studies on blood pressure control in type 2 diabetes<|>3)\n##\n(\"entity\"<|>RegazzoliD<|>PERSON<|>RegazzoliD is a researcher involved in studies on blood pressure control in type 2 diabetes<|>3)\n##\n(\"entity\"<|>祝之明<|>PERSON<|>祝之明 is a researcher and author of works on metabolic syndrome and cardiovascular diseases<|>4)\n##\n(\"entity\"<|>刘静<|>PERSON<|>刘静 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>3)\n##\n(\"entity\"<|>赵冬<|>PERSON<|>赵冬 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>3)\n##\n(\"entity\"<|>王薇<|>PERSON<|>王薇 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>3)\n##\n(\"entity\"<|>SmallHY<|>PERSON<|>SmallHY is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>3)\n##\n(\"entity\"<|>MontezanoAC<|>PERSON<|>MontezanoAC is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>3)\n##\n(\"entity\"<|>RiosFJ<|>PERSON<|>RiosFJ is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>3)\n##\n(\"entity\"<|>RanpuraV<|>PERSON<|>RanpuraV is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>3)\n##\n(\"entity\"<|>PulipatiB<|>PERSON<|>PulipatiB is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>3)\n##\n(\"entity\"<|>ChuD<|>PERSON<|>ChuD is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>3)\n##\n(\"entity\"<|>MaitlandML<|>PERSON<|>MaitlandML is a researcher involved in studies on blood pressure management in patients<|>3)\n##\n(\"relationship\"<|>WeberMA<|>ACCOMPLISH<|>WeberMA is a researcher involved in the ACCOMPLISH trial<|>8)\n##\n(\"relationship\"<|>JamersonK<|>ACCOMPLISH<|>JamersonK is a researcher involved in the ACCOMPLISH trial<|>8)\n##\n(\"relationship\"<|>BakrisGL<|>ACCOMPLISH<|>BakrisGL is a researcher involved in the ACCOMPLISH trial<|>8)\n##\n(\"relationship\"<|>RubinoDM<|>STEP 8<|>RubinoDM is a researcher involved in the STEP 8 trial<|>8)\n##\n(\"relationship\"<|>GreenwayFL<|>STEP 8<|>GreenwayFL is a researcher involved in the STEP 8 trial<|>8)\n##\n(\"relationship\"<|>KhalidU<|>STEP 8<|>KhalidU is a researcher involved in the STEP 8 trial<|>8)\n##\n(\"relationship\"<|>JastreboffAM<|>Tirzepatide<|>JastreboffAM is a researcher involved in the study of tirzepatide for obesity treatment<|>8)\n##\n(\"relationship\"<|>AronneLJ<|>Tirzepatide<|>AronneLJ is a researcher involved in the study of tirzepatide for obesity treatment<|>8)\n##\n(\"relationship\"<|>AhmadNN<|>Tirzepatide<|>AhmadNN is a researcher involved in the study of tirzepatide for obesity treatment<|>8)\n##\n(\"relationship\"<|>WigginsT<|>Bariatric Surgery<|>WigginsT is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>8)\n##\n(\"relationship\"<|>GuidozziN<|>Bariatric Surgery<|>GuidozziN is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>8)\n##\n(\"relationship\"<|>WelbournR<|>Bariatric Surgery<|>WelbournR is a researcher involved in the study of bariatric surgery and its effects on obesity-related diseases<|>8)\n##\n(\"relationship\"<|>Sj?str?mL<|>Bariatric Surgery<|>Sj?str?mL is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>8)\n##\n(\"relationship\"<|>LindroosAK<|>Bariatric Surgery<|>LindroosAK is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>8)\n##\n(\"relationship\"<|>PeltonenM<|>Bariatric Surgery<|>PeltonenM is a researcher involved in the study of lifestyle, diabetes, and cardiovascular risk factors after bariatric surgery<|>8)\n##\n(\"relationship\"<|>LiW<|>Metabolic Syndrome<|>LiW is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>8)\n##\n(\"relationship\"<|>SongF<|>Metabolic Syndrome<|>SongF is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>8)\n##\n(\"relationship\"<|>WangX<|>Metabolic Syndrome<|>WangX is a researcher involved in studies on metabolic syndrome and cardiovascular disease<|>8)\n##\n(\"relationship\"<|>WuM<|>Metabolic Syndrome<|>WuM is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>8)\n##\n(\"relationship\"<|>ShuY<|>Metabolic Syndrome<|>ShuY is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>8)\n##\n(\"relationship\"<|>WangL<|>Metabolic Syndrome<|>WangL is a researcher involved in the study of metabolic syndrome severity and CKD progression<|>8)\n##\n(\"relationship\"<|>XiaoJ<|>Metabolic Syndrome<|>XiaoJ is a researcher involved in the study of physical activity and metabolic syndrome risk<|>8)\n##\n(\"relationship\"<|>WuC<|>Metabolic Syndrome<|>WuC is a researcher involved in the study of physical activity and metabolic syndrome risk<|>8)\n##\n(\"relationship\"<|>XuG<|>Metabolic Syndrome<|>XuG is a researcher involved in the study of physical activity and metabolic syndrome risk<|>8)\n##\n(\"relationship\"<|>ZidekW<|>GOOD SURVEY<|>ZidekW is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>8)\n##\n(\"relationship\"<|>Naditch-Br?léL<|>GOOD SURVEY<|>Naditch-Br?léL is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>8)\n##\n(\"relationship\"<|>PerliniS<|>GOOD SURVEY<|>PerliniS is a researcher involved in the GOOD survey on blood pressure control and metabolic syndrome components<|>8)\n##\n(\"relationship\"<|>FerreiraJP<|>EMPA-REG OUTCOME<|>FerreiraJP is a researcher involved in the EMPA-REG OUTCOME trial<|>8)\n##\n(\"relationship\"<|>VermaS<|>EMPA-REG OUTCOME<|>VermaS is a researcher involved in the EMPA-REG OUTCOME trial<|>8)\n##\n(\"relationship\"<|>FitchettD<|>EMPA-REG OUTCOME<|>FitchettD is a researcher involved in the EMPA-REG OUTCOME trial<|>8)\n##\n(\"relationship\"<|>BerraC<|>Blood Pressure Control<|>BerraC is a researcher involved in studies on blood pressure control in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>ManfriniR<|>Blood Pressure Control<|>ManfriniR is a researcher involved in studies on blood pressure control in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>RegazzoliD<|>Blood Pressure Control<|>RegazzoliD is a researcher involved in studies on blood pressure control in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>祝之明<|>Metabolic Syndrome<|>祝之明 is a researcher and author of works on metabolic syndrome and cardiovascular diseases<|>8)\n##\n(\"relationship\"<|>刘静<|>Metabolic Syndrome<|>刘静 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>8)\n##\n(\"relationship\"<|>赵冬<|>Metabolic Syndrome<|>赵冬 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>8)\n##\n(\"relationship\"<|>王薇<|>Metabolic Syndrome<|>王薇 is a researcher involved in studies on metabolic syndrome and cardiovascular disease in China<|>8)\n##\n(\"relationship\"<|>SmallHY<|>Hypertension<|>SmallHY is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>8)\n##\n(\"relationship\"<|>MontezanoAC<|>Hypertension<|>MontezanoAC is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>8)\n##\n(\"relationship\"<|>RiosFJ<|>Hypertension<|>RiosFJ is a researcher involved in studies on hypertension due to antiangiogenic cancer therapy<|>8)\n##\n(\"relationship\"<|>RanpuraV<|>Hypertension<|>RanpuraV is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>8)\n##\n(\"relationship\"<|>PulipatiB<|>Hypertension<|>PulipatiB is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>8)\n##\n(\"relationship\"<|>ChuD<|>Hypertension<|>ChuD is a researcher involved in meta-analyses on hypertension risk with bevacizumab in cancer patients<|>8)\n##\n(\"relationship\"<|>MaitlandML<|>Blood Pressure Management<|>MaitlandML is a researcher involved in studies on blood pressure management in patients<|>8)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_7638bfcd7d6eb713f6d1fd88874467dfca197dcd08f9cd1bb8a559b44f363d5a_v2"}